Fundraising Fox

Verdiva Bio

2 known investors

verdivabio.com ↗

Verdiva Bio is a biotech company developing next-generation medicines for obesity, cardiometabolic diseases, and related metabolic conditions, focused on more convenient patient-friendly treatments. Its pipeline centers on rationally engineered peptides, including VRB-101 (an oral GLP-1 analog in Phase 2) and a portfolio of oral and injectable amylin-based candidates.

BiotechHealthtech

Investors · 2

OrbiMedNew York · $1M – $75M
RA CapitalBoston

In the news

Verdiva Bio Raises Over $410M in Series A Financingfinsmes.com · Jan 2025Verdiva Bio: Cardiometabolic Company Raises Over $410 Million (Series A)pulse2.com · Jan 2025Verdiva Bio launches with $411M Series A raise for next-gen oral and injectable treatments for obesity - Tech.eutech.eu · Jan 2025Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies | General Atlanticgeneralatlantic.com · Jan 2025

Frequently asked questions

What does Verdiva Bio do?
Verdiva Bio is a biotech company developing next-generation medicines for obesity, cardiometabolic diseases, and related metabolic conditions, focused on more convenient patient-friendly treatments. Its pipeline centers on rationally engineered peptides, including VRB-101 (an oral GLP-1 analog in Phase 2) and a portfolio of oral and injectable amylin-based candidates.
Who are Verdiva Bio's investors?
Verdiva Bio's investors include OrbiMed, RA Capital.